Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. (NASDAQ: SIBN) files a range of reports with the U.S. Securities and Exchange Commission that provide detailed insight into its sacropelvic-focused medical device business. This SEC filings page brings together those documents and pairs them with AI-powered summaries to help interpret the information that matters for SIBN stock.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, SI-BONE discloses its revenue from sacroiliac joint fusion and related sacropelvic procedures, gross margin, operating expenses, net loss, adjusted EBITDA, cash and investments, and other key financial metrics. These filings also describe risk factors, clinical evidence supporting its technologies, and considerations related to reimbursement, supply chain, and the healthcare operating environment.
Current reports on Form 8-K are used by SI-BONE to announce material events such as quarterly financial results, preliminary unaudited revenue and cash figures, and leadership or board changes. For example, recent 8-K filings have referenced press releases on quarterly results, preliminary full-year revenue, and executive transitions, as well as consulting and retirement agreements with senior leaders and directors.
This page also provides access to other SEC documents that may include registration statements and proxy materials, which can address topics such as equity compensation, board composition, and corporate governance. For investors interested in insider activity, Forms 3, 4, and 5 (when filed) detail transactions by directors and officers in SIBN shares.
AI-generated highlights on this platform are designed to make SI-BONE’s filings easier to navigate by surfacing key figures, summarizing management’s discussion of performance, and pointing to sections that discuss sacropelvic technologies, clinical evidence, and reimbursement dynamics. Real-time updates from EDGAR ensure that new 10-K, 10-Q, and 8-K filings for SI-BONE, Inc. are available promptly, while AI summaries help reduce the time required to understand their implications.
SI-BONE, Inc. filed a shelf registration on
The prospectus states the companys common stock trades on the Nasdaq Global Market under the symbol SIBN, with a reported last sale price of
SI-BONE, Inc. files its annual report describing a fast‑growing sacropelvic implant business that still operates at a loss. The company focuses on minimally invasive solutions for sacroiliac joint dysfunction, thoracolumbar fixation and fusion, and pelvic trauma, built around its 3D‑printed titanium iFuse product family.
Management estimates a U.S. addressable market above $3.5 billion, including about $2.4 billion for sacroiliac joint fusion and $1.0 billion for thoracolumbar fixation and fusion. Net loss narrowed to $18.9 million in 2025, down from $30.9 million in 2024 and $43.3 million in 2023, with an accumulated deficit of $450.3 million.
As of June 30 2025, non‑affiliate common stock had an aggregate market value of approximately $0.8 billion, and 44,165,287 shares were outstanding as of February 18 2026. The report highlights extensive clinical data, breakthrough device designations, CMS add‑on payments, significant competitive pressures, regulatory complexity, and a continued risk that the company may not achieve sustained profitability.
SI-BONE, Inc. reported strong fourth quarter and full-year 2025 results with improving profitability and issued 2026 guidance. Worldwide revenue reached $56.3 million in Q4 2025, up 15.0%, and $200.9 million for 2025, up 20.2%, with gross margin near 79%.
Net loss narrowed to $1.6 million in Q4 and $18.9 million for 2025, while adjusted EBITDA turned positive at $5.1 million in Q4 and $8.9 million for the year. The company generated positive operating cash flow of $1.7 million and free cash flow of $0.4 million in Q4, ending 2025 with $147.8 million in cash and equivalents and $35.6 million in borrowings.
For 2026, SI-BONE guides to worldwide revenue of $228.5–$232.5 million, implying ~14–16% growth, with gross margin of about 78% and higher positive adjusted EBITDA. The company also signed a new long-term lease for larger facilities and promoted CFO Anshul Maheshwari to Chief Operating Officer.
SI-BONE, Inc. reporting person Anthony J. Recupero reported multiple open-market sales of common stock on February 17, 2026 totaling 21,049 shares at weighted-average prices around the mid‑$15 range. The filing states these shares were sold under a “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units, and therefore were not discretionary trades. After these sales, Recupero reported ownership of 243,418 shares of common stock, which the footnotes state includes 83,423 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. reported that executive Michael A. Pisetsky, SVP of Operations & Administration and Chief Legal Officer, received several stock awards and sold shares primarily to cover taxes. On February 16, 2026, he acquired 58,720 shares of common stock and two additional grants of 9,787 shares each as restricted stock unit awards, at a stated price of $0.00 per share, reflecting equity compensation that will vest over multi-year periods based on service and, for one grant, relative total shareholder return performance.
On February 17, 2026, he executed open-market sales totaling 20,756 shares of common stock at weighted average prices around $15.31–$15.41 per share. Footnotes state these sales were required to satisfy tax withholding obligations from RSU vesting through “sell to cover” transactions and were not discretionary trades. After these transactions, he continued to hold a substantial share position, including 157,176 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. director and Chief Executive Officer Laura Francis reported a mix of stock awards and sales. On
SI-BONE, Inc.’s Chief Financial Officer Anshul Maheshwari reported a mix of equity awards and related share sales. On
On
OrbiMed Capital LLC and OrbiMed Advisors LLC report that they no longer own any shares of SI-BONE, Inc. common stock. As of the event date of 12/31/2025, each reporting person discloses beneficial ownership of 0 shares, representing 0.0% of SI-BONE’s common stock.
They report no sole or shared voting or dispositive power over any SI-BONE shares and confirm they now own 5 percent or less of the class. The firms state the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.
American Century entities and the Stowers Institute report significant ownership stakes in Si-Bone, Inc. common stock in an amended Schedule 13G. American Century Investment Management, American Century Companies, and the Stowers Institute each report beneficial ownership of 2,300,508 shares, representing 5.3% of the class.
American Century Mutual Funds separately reports beneficial ownership of 1,779,575 shares, or 4.1% of the common stock. The filers certify that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Si-Bone.
SI-BONE, Inc. (SIBN) received an updated Schedule 13G/A from Brown Advisory and related entities reporting their passive ownership in the company’s common stock as of 12/31/2025. Brown Advisory Inc and its listed subsidiaries report beneficial ownership of 2,513,268 shares, representing 5.79 % of the outstanding common stock.
The shares are held across multiple affiliated entities, including Brown Advisory LLC, Brown Investment Advisory & Trust, Signature Financial Management, Inc., and Brown Advisory Ltd, largely through investment companies and managed accounts. The group certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.